GSK (LON:GSK) Stock Price Crosses Above 200-Day Moving Average - Here's Why

GSK plc (LON:GSK - Get Free Report) crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of GBX 1,399.45 ($18.97) and traded as high as GBX 1,518.50 ($20.58). GSK shares last traded at GBX 1,485 ($20.12), with a volume of 9,166,149 shares trading hands.

Analysts Set New Price Targets

A number of analysts have recently issued reports on GSK shares. JPMorgan Chase & Co. reaffirmed an "underweight" rating on shares of GSK in a report on Friday, March 28th. Shore Capital restated a "buy" rating on shares of GSK in a research note on Wednesday, April 30th. One analyst has rated the stock with a sell rating and five have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of GBX 1,862.50 ($25.24).

GSK Stock Performance

The stock has a market cap of £61.35 billion, a P/E ratio of 24.42, a PEG ratio of 1.24 and a beta of 0.31. The company has a debt-to-equity ratio of 114.64, a current ratio of 0.81 and a quick ratio of 0.73. The firm's 50-day moving average price is GBX 1,397.95 and its 200-day moving average price is GBX 1,400.43.

GSK (LON:GSK - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The company reported GBX 44.90 ($0.61) earnings per share (EPS) for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. Sell-side analysts expect that GSK plc will post 175.980975 earnings per share for the current fiscal year.

Insider Activity at GSK

In other GSK news, insider Emma Walmsley sold 5,473 shares of GSK stock in a transaction on Tuesday, May 6th. The shares were sold at an average price of GBX 1,449 ($19.64), for a total transaction of £79,303.77 ($107,472.25). Also, insider Wendy Becker acquired 536 shares of the company's stock in a transaction on Thursday, March 20th. The shares were purchased at an average cost of GBX 1,515 ($20.53) per share, with a total value of £8,120.40 ($11,004.74). 1.61% of the stock is currently owned by insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.